Abstract: The instant invention provides binding proteins (“CD38-binding proteins”) which each comprise (1) a CD38-binding region for cell-targeting and (2) a Shiga toxin A Subunit effector polypeptide (“Shiga toxin effector polypeptide”). The Shiga toxin effector polypeptide components of the CD38-binding proteins may comprise a combination of mutations relative to a wild-type Shiga toxin sequence providing (1) de-immunization and/or (2) a reduction in protease sensitivity; wherein each Shiga toxin effector polypeptide retains one or more Shiga toxin function, such as, e.g., stimulating cellular internalization, directing intracellular routing, catalytic activity, and/or potent cytotoxicity. The CD38-binding proteins may have one or multiple uses, e.g., the selective killing of a specific CD38-expressing cell-type; and more generally, for the diagnosis and treatment of cancers and disorders involving CD38-expressing cells, e.g., in CD38-positive hematopoietic cancers such as multiple myeloma.
Type:
Grant
Filed:
January 23, 2020
Date of Patent:
August 1, 2023
Assignees:
Millennium Pharmaceuticals, Inc., Molecular Templates, Inc.
Inventors:
Nibedita Chattopadhyay, Eric Poma, Erin Willert
Abstract: The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule.
Type:
Grant
Filed:
March 17, 2020
Date of Patent:
August 1, 2023
Assignee:
NexImmune, Inc.
Inventors:
Bruce McCreedy, Timothy David Jones, Francis Joseph Carr
Abstract: The present invention provides combinations and methods using same for the treatment of malignancy, particularly a myeloid malignancy such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). The combination may comprise an antibody or antigen-binding fragment thereof that binds to CD70, and an inhibitor of BCL-2. In certain embodiments, the antibody is ARGX-110 (cusatuzumab). In certain embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the combination provides synergistic treatment of AML. The combination may additionally comprise at least one additional anti-cancer agent.
Type:
Grant
Filed:
December 18, 2019
Date of Patent:
August 1, 2023
Assignees:
ARGENX BV, University of Bern
Inventors:
Johannes De Haard, Samson Fung, Nicolas Leupin, Adrian Ochsenbein, Carsten Riether, Luc Van Rompaey
Abstract: A Twin Immune Cell Engager (TWICE) is a kit or composition for treating cancer comprising a first component and second component. Each component comprises a targeting moiety that binds a tumor antigen expressed by the cancer or an antigen expressed by a non-cancer cell in the tumor microenvironment. In some embodiments, the first and second components each comprise an immune cell binding domain capable of immune cell binding activity when binding the immune cell binding domain in the other component, and a complementary binding domain capable of binding to a complementary antigen when binding the complementary binding domain in the other component. In some embodiments, the first and/or second components comprise a complementary functional domain with activity when targeted to the cancer cell or its microenvironment.
Type:
Grant
Filed:
December 16, 2019
Date of Patent:
July 18, 2023
Assignee:
Revitope Limited
Inventors:
Martin Preyer, Allison Colthart, Pamela Weinstein, Patrick Wiencek, Emma Geiger, Werner Meier
Abstract: Provided herein are tumor-antigen VCX/Y specific peptides and engineered VCX/Y specific T cell receptors. Also provided herein are methods of generating VCX/Y-specific immune cells and their use for the treatment of cancer. In addition, the VCX/Y-specific peptides may be used as a vaccine.
Type:
Grant
Filed:
December 28, 2017
Date of Patent:
July 11, 2023
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).
Type:
Grant
Filed:
February 2, 2019
Date of Patent:
July 4, 2023
Assignee:
Adagene Inc.
Inventors:
Peter Peizhi Luo, Fangyong Du, Zhongzong Pan, Guizhong Liu
Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulator are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.
Type:
Grant
Filed:
February 20, 2020
Date of Patent:
June 6, 2023
Assignee:
Gensun Biopharma, Inc.
Inventors:
Jackie Sheng, Margaret Karow, Wei Zhang
Abstract: The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positive metastatic breast cancer in patients who did not receive prior chemotherapy or biologic therapy with a HER2 antibody binding essentially to epitope 2C4, a HER2 antibody binding essentially to epitope 4D5, and a taxane. The invention further comprises extending survival of such patients by the combination therapy of the present invention. In a preferred embodiment, the treatment involves administration of trastuzumab, pertuzumab and docetaxel.
Type:
Grant
Filed:
June 2, 2020
Date of Patent:
May 23, 2023
Assignee:
Genentech, Inc.
Inventors:
Virginia Paton, Anne Blackwood Chirchir, Pam Klein
Abstract: The present disclosure relates to a novel anti-HER2 antibody or an antigen-binding fragment thereof used in the prevention or treatment of cancer, a chimeric antigen receptor including the same, and uses thereof. The antibody of the present disclosure is an antibody that specifically binds to HER2 which is highly expressed in cancer cells (particularly, breast cancer or gastric cancer cells), and binds to an epitope that is different from an epitope to which trastuzumab binds.
Type:
Grant
Filed:
May 22, 2020
Date of Patent:
May 16, 2023
Assignee:
GC Cell Corporation
Inventors:
Jong Seo Lee, Kyu Tae Kim, Young Ha Lee, In Sik Hwang, Bong Kook Ko, Eunji Choi, You-Sun Kim, Jeongmin Kim, Miyoung Jung, Hoyong Lim, Sungyoo Cho
Abstract: The present disclosure is directed to antibodies that bind to DC-HIL on the surface of myeloid-derived suppressor cells, and thus antagonize the T cell suppressor function of these cells, as well as their use in diagnosing and treating cancers such as melanoma.
Type:
Grant
Filed:
December 31, 2019
Date of Patent:
May 16, 2023
Assignee:
The Board of Regents of The University of Texas System
Abstract: Described herein are systems and methods for treating, inhibiting, or ameliorating X-linked disorders including Wiskott-Aldrich Syndrome (WAS) and X-linked thrombocytopenia (XLT) in subjects that have been identified or selected as being ones that would benefit from a therapy to treat, inhibit, or ameliorate WAS or XLT. The systems include nuclease and vector donor constructs configured for co-delivery to modify endogenous WAS locus.
Abstract: The present invention provides binding molecules that include an IgM, IgA, IgG/IgM or IgG/IgA antibody with a modified J-chain that includes a binding moiety that antagonizes a T-cell inhibitory signaling pathway, and their uses.
Type:
Grant
Filed:
September 30, 2016
Date of Patent:
May 2, 2023
Assignee:
IGM Biosciences, Inc.
Inventors:
Bruce A. Keyt, Leonard G. Presta, Ramesh Baliga
Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.
Abstract: [Problem to be Solved] Provided is an effective and safe method for treating or preventing a cancer using aAVC. [Solution] The present invention finds suitable ranges of the dose of ?-GalCer loaded on aAVC cell surface, and the amount of ?-GalCer loaded on aAVC cell surface in a pharmaceutical composition comprising aAVC, which are preferred in terms of securing effectiveness and safety in the treatment and prevention of a cancer using aAVC, and provides an effective and safe method for treating or preventing a cancer using aAVC, aAVC for effective and safe treatment or prevention of a cancer, and a pharmaceutical composition comprising the same, etc.
Abstract: Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
Type:
Grant
Filed:
April 8, 2020
Date of Patent:
March 28, 2023
Assignee:
SANOFI
Inventors:
Christian Beil, Jochen Beninga, Joerg Birkenfeld, Gary J. Nabel, Huawei Qiu, Ercole Rao, Joerg Regula, Edward Seung, Ronnie Wei, Lan Wu, Zhen Xing, Ling Xu, Zhi-Yong Yang, Béatrice Cameron, Tarik Dabdoubi, Cendrine Lemoine, Catherine Prades
Abstract: The present disclosure relates to the use of anti-PAD4 autoantibodies as a clinical biomarker for rheumatoid arthritis (RA) treatment. The disclosure further provides an assay to detect anti-PAD4 autoantibodies, assay kits for the detection of anti-PAD4 autoantibodies, as well as computer implemented diagnostic methods.
Type:
Grant
Filed:
May 23, 2017
Date of Patent:
March 28, 2023
Assignee:
MEDIMMUNE LIMITED
Inventors:
Rachel Patricia Moate, Alex Godwood, Ethan Paul Grant, Martin Michael Kari Schwickart, Carlos Chavez, Meina Liang, Tomas Mikael Mustelin, Zhengbin Yao, Koustubh Ranade
Abstract: The present invention provides a novel PSMA binding antibody termed 10B3 and pharmaceutical and diagnostic uses of the antibody 10B3. The PSMA antibody 10B3 does not cross-compete with the state of the art PMSA binding antibody J591 and has a reduced induction of antigen shift compared to J591 and a unique reactivity with squamous cell carcinoma (SCC) cells of different origin.
Type:
Grant
Filed:
January 16, 2017
Date of Patent:
March 28, 2023
Assignees:
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts, Eberhard Karls Universität Tübingen
Inventors:
Helmut Salih, Fabian Vogt, Gundram Jung, Latifa Zekri-Metref
Abstract: The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.
Type:
Grant
Filed:
October 29, 2019
Date of Patent:
February 28, 2023
Assignee:
LAVA THERAPEUTICS N.V.
Inventors:
Johannes Jelle Van Der Vliet, Tanja Denise De Gruijl, Hendrik Marinus Willem Verheul, Renée Cornelia Gerarda De Bruin, Roeland Lameris